1. |
Age-related macular degeneration therapies eyed up |
|
Inpharma Weekly,
Volume &NA;,
Issue 1365,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1365,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1365,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1365,
2002,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
AN-207 inhibits growth of ES-2 ovarian cancers |
|
Inpharma Weekly,
Volume &NA;,
Issue 1365,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
Micafungin: superiority over fluconazole in HSCT recipients |
|
Inpharma Weekly,
Volume &NA;,
Issue 1365,
2002,
Page 7-8
Raewyn Poole,
Preview
|
|
摘要:
Opportunistic fungal infections are associated with high morbidity and mortality rates among immunocompromised patients such as recipients of organ, bone marrow or stem cell transplants, as well as patients with HIV infections and those receiving chemotherapy for cancer. Effective treatment and prevention of such infections, which are most commonly caused by theAspergillusandCandidaspecies, is therefore of increasing importance. A study presented recently at the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [San Diego; September 2002] showed that the cell wall synthesis inhibitor micafungin [FK 463; 'Funguard'] was superior to fluconazole ['Diflucan'] in preventing invasive fungal infections in patients receiving haematopoetic stem cell transplants (HSCT). The treatment success rate was significantly higher, in micafungin, compared with fluconazole, recipients; furthermore, the requirement for empirical antifungal treatment was significantly lower in patients treated with micafungin.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
C1-inhibitor may reduce reperfusion injury in acute MI |
|
Inpharma Weekly,
Volume &NA;,
Issue 1365,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1365,
2002,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
Cisplatin successful in neoplastic pericardial effusion |
|
Inpharma Weekly,
Volume &NA;,
Issue 1365,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
Alendronic acid superior to risedronic acid for osteoporosis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1365,
2002,
Page 11-12
Robert H Carlson,
Preview
|
|
摘要:
The growing demand for medications to treat or prevent osteoporosis is one reason for the rapid development of drugs in the bisphosphonate class. Researchers and clinicians are enthusiastic because each new generation of bisphosphonates has shown increased efficacy and greater convenience in administration compared with predecessors. At the 24th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) [San Antonio, US; September 2002], considerable attention was devoted to bisphosphonates, including the presentation of results of the first head-to-head study comparing the efficacy of alendronic acid ['Fosamax'] and risedronic acid ['Actonel'] for the treatment of postmenopausal osteoporosis. Although both treatments were effective, weekly administration of alendronic acid provided significantly greater reductions in bone resorption, and larger increases in spine and hip bone mineral density (BMD), compared with daily doses of risedronic acid. In a separate study, the longest conducted with a nonhormonal osteoporosis therapy to date, alendronic acid was shown to provide continued improvements in bone mineral density over a 10-year period.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|